Brief: Vaxxinity’S Cholesterol Vaccine Candidate Successfully Lowers Ldl-C Preclinical Data Published

Vaxxinity

15/02/2024 13:50

Feb 15 (Reuters) - Vaxxinity Inc  VAXX.O :
    * VAXXINITY’S CHOLESTEROL VACCINE CANDIDATE SUCCESSFULLY
LOWERS
LDL-C: PRECLINICAL DATA PUBLISHED
    *  A PHASE 1 TRIAL OF VXX-401 IS ONGOING, WITH TOPLINE
RESULTS
EXPECTED MID-2024
    * VXX-401 IS WELL-TOLERATED, WITH NO SAFETY SIGNALS
OBSERVED, AND
ROBUSTLY REDUCES LDL-C IN CYNOMOLGUS MONKEYS

Source text for Eikon:  ID:nGNX9n4t3 
Further company coverage:  VAXX.O 

 ((Reuters.Briefs@thomsonreuters.com;))